Úneta a la lista de correo. Requiere aprobación
Correo electrónico:
Consultar este grupo

viernes, 27 de febrero de 2015

VII Simposio Internacional de Bioseguridad y Biocustodia #SIBB15

Publicado el 17/Feb/2015

En su 7a. edición, el Simposio Internacional de Bioseguridad y Biocustodia 2015 (#SIBB15), la Asociación Mexicana de Bioseguridad A.C. en colaboración con el Instituto Nacional de Enfermedades Respiratorias se realizará del 3 al 6 de Junio de 2015. En este VII Simposio se presentan un programa de cursos presimposio, pláticas magistrales, mesas de discusión, seminarios y exposición comercial que congregarán a expertos e interesados de México y el extranjero.


¿Quién debe asistir?

Profesionales de la salud humana, ámbito agropecuario e industrial involucrados en temas de bioseguridad, biocontención, gestión de riesgos biológicos y biotecnológicos, involucrados en manejo de materiales biológico infecciosos. Este simposio de bioseguridad (SIBB) es una reunión especializada en el entrenamiento, análisis, discusión y planteamiento de propuestas alrededor de la seguridad biológica y los materiales biológico infecciosos en México y nuestro entorno. El SIBB es organizado por la Asociación Mexicana de Bioseguridad A.C. desde 2009. 

Por favor consulten toda la información en la Página del VII Simposio

CONSULTE EL PROGRAMA

-----------------------------------------------------------
Sigue este Blog en Facebook y Twitter

Membresías AMEXBIO 2015

Para apoyar el cumplimiento de los objetivos de la Asociación Mexicana de Bioseguirdad A.C. se está llevando a cabo la campaña de renovación y actualización de membresía 2014 - 2015, la cual nos permitirá desarrollar distintos proyectos como asambleas, simposio, cursos en línea, seminarios, talleres, y otorgar un mayor número de becas para los asistentes. Una de las fuentes de ingreso de AMEXBIO son las aportaciones de los miembros, por lo que invitamos a actualizar su membresía o unirse como miembro activo.

Los BENEFICIOS que obtendrás al pagar tu membresía de 2015 son:
  1. Cuotas preferenciales para el Simposio Anual, cursos en línea, eventos, seminarios y productos que organice y promueva AMEXBIO.
  2. Accesos a la biblioteca de videos y cursos en nuestro portal de Formación Académica, a través de clave personalizada que te llegará al pagar tu membresía.
  3. Poder conocer las diferentes convocatorias de las instituciones que apoyan con recursos o descuentos para participar en eventos nacionales e internacionales sobre temas de bioseguridad.
  4. Contar con su perfil académico y poder participar como profesor en nuestros cursos en línea o cursos presenciales.
  5. Participar activamente en todos los eventos académicos que organice nuestra Asociación.
  6. Constancia de miembro activo.
Para lograr este objetivo, aprovecha el “Plan 2015 AMEXBIO” que consiste en:

A partir de 01-Febrero-2015, el costo de la Membresía se incrementa a $900.- MXN.
  1. Nuevos miembros. Si no eres miembro (Estatus visitante o en blanco): Los profesores o investigadores de nuevo ingreso deberán enviar el pago de $ 800.00 (Antes del 31 de Enero),  actualizar su perfil en la página de miembros: www.amexbio.wildapricot.org y enviar la documentación solicitada, al correo electrónico de tesoreria(arroba)amexbio.org. Por favor revisen la convocatoria en: http://amexbio.org/docs/convocatoriaM.pdf. A partir del 1 de Febrero, el costo será de $900.- (MXN). 
  2. Renovaciones miembros activos.  Si ya eres miembro y estas al corriente (Estatus Active): Paga el mismo importe del 2014 de $ 800.00 (actualiza tu perfil, hay campos nuevos). A partir del 01 de Febrero de 2015, incrementa a $ 900.- MXN
  3. Renovaciones vencidas, pagos pendientes. Si ya eres miembro pero no estás al corriente (Estatus Pending Renewal o Lapsed): Los miembros fundadores, titulares y numerarios que hayan dejado de pagar por varios años, podrán ponerse al corriente con todas sus cuotas al pagar $ 400.00, además de pagar lo correspondiente a la membresía 2015 de $ 800.00. En total del depósito sería de $ 1,200.00 para ponerse al corriente y renovar hasta febrero de 2016. (actualiza tu perfil, hay campos nuevos).
Las solicitudes nuevas se reciben de ENERO a MAYO de cada año!

Depósito bancario a nombre de:Cliente: ASOCIACION MEXICANA DE BIOSEGURIDAD A.C.
Banco: BANAMEX
CLABE interbancaria: 002180024179950244
Sucursal: 0241
Cuenta: 7995024
Referencia: (nombre del miembro)
Enviar el comprobante de depósito escaneado y datos de facturación (si es necesario) y en el caso de nuevo ingreso, los documentos solicitados, al siguiente correo electrónico: tesoreria(arroba)amexbio.org. Se emitirá la factura correspondiente, la emisión de la clave de acceso para el portal de Formación Académica, así como la constancia de membresía, que se enviarán por correo electrónico.

Por favor ayúdanos a distribuir esta información entre tus contactos que les pueda interesar en participar en AMEXBIO.

Atentamente

Dr. Saúl López Silva
Presidente
Consejo Directivo AMEXBIO

-----------------------------------------------------------
Sigue este Blog en Facebook y Twitter

Laboratory Test Support for #Ebola Patients Within a High-Containment Facility

Two adult United States (US) nationals contracted the Ebola virus while on a humanitarian mission in Africa amidst a large Ebola outbreak there. They were admitted to our medical center (Emory University Hospital in Atlanta, GA) during the first week of August 2014 for treatment. Both survived their illness and were released after approximately 3 weeks of inpatient care. We received approximately 3 days’ advance notice that the first patient would be transported from Africa to our medical center; the second patient arrived 3 days after the first. The diagnosis in each case had been confirmed virologically by detecting Ebola-specific nucleic acid in blood specimens sent to a World Health Organization laboratory in Europe; however, few details of either patient’s condition had been available to us before their arrival. Herein, we summarize the approach we used to plan for and provide laboratory diagnostic testing during their treatment.
REFERENCE:
Hill CE, et al. Laboratory test support for ebola patients within a high-containment facility. Lab Med. 2014 Summer;45(3):e109-11.
-----------------------------------------------------------
Sigue este Blog en Facebook y Twitter

miércoles, 25 de febrero de 2015

Transmission of #Ebola Viruses

Available evidence demonstrates that direct patient contact and contact with infectious body fluids are the primary modes for Ebola virus transmission, but this is based on a limited number of studies. Key areas requiring further study include (i) the role of aerosol transmission (either via large droplets or small particles in the vicinity of source patients), (ii) the role of environmental contamination and fomite transmission, (iii) the degree to which minimally or mildly ill persons transmit infection, (iv) how long clinically relevant infectiousness persists, (v) the role that “superspreading events” may play in driving transmission dynamics, (vi) whether strain differences or repeated serial passage in outbreak settings can impact virus transmission, and (vii) what role sylvatic or domestic animals could play in outbreak propagation, particularly during major epidemics such as the 2013–2015 West Africa situation. In this review, we address what we know and what we do not know about Ebola virus transmission. We also hypothesize that Ebola viruses have the potential to be respiratory pathogens with primary respiratory spread.
REFERENCE:
Osterholm MT, et al. Transmission of ebola viruses: what we know and what we do not know. MBio. 2015 Feb 19;6(2).
-----------------------------------------------------------
Sigue este Blog en Facebook y Twitter

lunes, 23 de febrero de 2015

#Ebola outbreak in Western Africa 2014: what is going on with Ebola virus?

The 2014 outbreak of Ebola virus disease (EVD) in West Africa, caused by Ebola virus (Zaire Ebola virus species), is the largest outbreak of EVD in history. It cause hemorrhagic fever in human and nonhuman primates with high mortality rate up to 90% and can be transmitted by direct contact with blood, body fluids, skin of EVD patients or persons who have died of EVD. As of December 17, 2014, 450 healthcare personnel are known to have been infected with Ebola, of whom 244 died. For development of Ebola vaccine and treatment are highly difficult due to its dangerous and accessibility that requires biosafety level 4 (BSL-4) to conduct experiment. Also there is no specific vaccine and treatment for Ebola virus; however, many candidate vaccines and antiviral-drugs such as ZMapp and TKM-Ebola are being developed for Ebola virus disease. In this review, we focus on the epidemiology of 2014 outbreak of Ebola virus and candidate agent for preventing and curing from Ebola virus.
REFERENCE:
Na W, et al. Ebola outbreak in Western Africa 2014: what isgoing on with Ebola virus? Clin Exp Vaccine Res. 2015 Jan;4(1):17-22. Review.
-----------------------------------------------------------
Sigue este Blog en Facebook y Twitter

jueves, 19 de febrero de 2015

Evaluation of Virus Inactivation by Formaldehyde to Enhance Biosafety

Formaldehyde (FA) fixation of infectious samples is a well-established protocol in diagnostic electron microscopy of viruses. However, published experimental data that demonstrate virus inactivation by these fixation procedures are lacking. Usually, fixation is performed immediately before the sample preparation for microscopy. The fixation procedure should transform viruses in a non-infectious but nonetheless structurally intact form in order to allow a proper diagnosis based on morphology. FA provides an essential advantage in comparison to other disinfectants, because it preserves the ultrastructure of biological material without interfering significantly with the preparation (i.e., the negative staining) and the detection of viruses. To examine the efficiency of FA inactivation, we used Vaccinia virus, Human adenovirus and Murine norovirus as models and treated them with FA under various conditions. Critical parameters for the inactivation efficiency were the temperature, the duration of the FA treatment, and the resistance of the virus in question. Our results show that FA inactivation at low temperature (4 °C) bears a high risk of incomplete inactivation. Higher temperatures (25 °C) are more efficient, although they still require rather long incubation times to fully inactivate a complex and highly robust virus like Vaccinia. A protocol, which applied 2% buffered FA for 60 min and a temperature-shift from 25 to 37 °C after 30 min was efficient for the complete inactivation of all test viruses, and therefore has the potential to improve both and speed of diagnostic electron microscopy.
REFERENCE:
Möller L, Schünadel L, Nitsche A, Schwebke I, Hanisch M, Laue M. Evaluation of Virus Inactivation by Formaldehyde to Enhance Biosafety of Diagnostic Electron Microscopy. Viruses. 2015 Feb 10;7(2):666-679.
-----------------------------------------------------------
Sigue este Blog en Facebook y Twitter

martes, 3 de febrero de 2015

Guidance on regulations for the Transport of Infectious Substances 2015-2016

Applicable as from 1 January 2015


Authors:
WHO

Publication details 

Number of pages38 
Publication date2015
LanguagesEnglish
WHO reference numberWHO/HSE/GCR/2015.2

Downloads

Overview

This publication provides information for identifying, classifying, marking, labelling, packaging, documenting and refrigerating infectious substances for transportation and ensuring their safe delivery. 

The document provides practical guidance to facilitate compliance with applicable international regulations for the transport of infectious substances by all modes of transport, both nationally and internationally, and include the changes that apply from 1 January 2015. The current revision replaces the document issued by the World Health Organization (WHO) in 2012 (document WHO/CDS/EPR/2012.12). This publication, however, does not replace national and international transport regulation.

Descarga http://apps.who.int/iris/bitstream/10665/149288/1/WHO_HSE_GCR_2015.2_eng.pdf?ua=1&ua=1

lunes, 2 de febrero de 2015

Survey of Safety Practices Among Hospital Laboratories in Ethiopia

BACKGROUND: Unsafe working practices, working environments, disposable waste products, and chemicals in clinical laboratories contribute to infectious and non-infectious hazards. Staffs, the community, and patients are less safe. Furthermore, such practices compromise the quality of laboratory services. We conducted a study to describe safety practices in public hospital laboratories of Oromia Regional State, Ethiopia.
METHOD: Randomly selected ten public hospital laboratories in Oromia Regional State were studied from Oct 2011- Feb 2012. Self-administered structured questionnaire and observation checklists were used for data collection. The respondents were heads of the laboratories, senior technicians, and safety officers. The questionnaire addressed biosafety label, microbial hazards, chemical hazards, physical/mechanical hazards, personal protective equipment, first aid kits and waste disposal system. The data was analyzed using descriptive analysis with SPSS version16 statistical software.
RESULT: All of the respondents reported none of the hospital laboratories were labeled with the appropriate safety label and safety symbols. These respondents also reported they may contain organisms grouped under risk group IV in the absence of microbiological safety cabinets. Overall, the respondents reported that there were poor safety regulations or standards in their laboratories. There were higher risks of microbial, chemical and physical/mechanical hazards.
CONCLUSION: Laboratory safety in public hospitals of Oromia Regional State is below the standard. The laboratory workers are at high risk of combined physical, chemical and microbial hazards. Prompt recognition of the problem and immediate action is mandatory to ensure safe working environment in health laboratories.
REFERENCIA:
Sewunet T et al. Survey of Safety Practices Among Hospital Laboratories in Oromia Regional State, Ethiopia. Ethiop J Health Sci. Oct 2014; 24(4): 307–310.

-----------------------------------------------------------
Sigue este Blog en Facebook y Twitter

jueves, 29 de enero de 2015

Feasibility of establishing a BSL3 tuberculosis culture lab in a resource-limited setting

Background: Despite the recent innovations in tuberculosis (TB) and multi-drug resistant TB (MDR-TB) diagnosis, culture remains vital for difficult-to-diagnose patients, baseline and end-point determination for novel vaccines and drug trials. Herein, we share our experience of establishing a BSL-3 culture facility in Uganda as well as 3-years performance indicators and post-TB vaccine trials (pioneer) and funding experience of sustaining such a facility.
Methods: Between September 2008 and April 2009, the laboratory was set-up with financial support from external partners. After an initial procedure validation phase in parallel with the National TB Reference Laboratory (NTRL) and legal approvals, the laboratory registered for external quality assessment (EQA) from the NTRL, WHO, National Health Laboratories Services (NHLS), and the College of American Pathologists (CAP). The laboratory also instituted a functional quality management system (QMS). Pioneer funding ended in 2012 and the laboratory remained in self-sustainability mode.
Results: The laboratory achieved internationally acceptable standards in both structural and biosafety requirements. Of the 14 patient samples analyzed in the procedural validation phase, agreement for all tests with NTRL was 90% (P <0.01). It started full operations in October 2009 performing smear microscopy, culture, identification, and drug susceptibility testing (DST). The annual culture workload was 7,636, 10,242, and 2,712 inoculations for the years 2010, 2011, and 2012, respectively. Other performance indicators of TB culture laboratories were also monitored. Scores from EQA panels included smear microscopy >80% in all years from NTRL, CAP, and NHLS, and culture was 100% for CAP panels and above regional average scores for all years with NHLS. Quarterly DST scores from WHO-EQA ranged from 78% to 100% in 2010, 80% to 100% in 2011, and 90 to 100% in 2012.
Conclusions: From our experience, it is feasible to set-up a BSL-3 TB culture laboratory with acceptable quality performance standards in resource-limited countries. With the demonstrated quality of work, the laboratory attracted more research groups and post-pioneer funding, which helped to ensure sustainability. The high skilled experts in this research laboratory also continue to provide an excellent resource for the needed national discussion of the laboratory and quality management systems.
REFERENCIA:
Ssengooba, W., et al. Feasibility of establishing a biosafety level 3 tuberculosis culture laboratory of acceptable quality standards in a resource-limited setting: an experience from Uganda. Health Research Policy and Systems 2015, 13:4

-----------------------------------------------------------
Sigue este Blog en Facebook y Twitter

lunes, 26 de enero de 2015

License to Serve - U.S. Trainees and the #Ebola Epidemic

Before medical school, Sara L., now a fourth-year resident, worked for 6 years as a microbiologist at the Centers for Disease Control and Prevention. While there, she focused on hemorrhagic fevers, and she went to West Africa several times to assist in outbreaks. Indeed, until recently, Sara was one of only a few hundred people in the United States who was trained to work in a biosafety level 4 “spacesuit” laboratory, which requires the same personal protective equipment (PPE) needed for working with Ebola. As the current Ebola epidemic exploded, and after careful deliberation, Sara sought and secured a position with an international aid organization, got approval from her residency program's leadership, found coverage for her time away, and 6 weeks later, was set to deploy. Then she got a call from her institution's risk-management department with disappointing news: the institution would not support her deployment.

Rosenbaum L. License to Serve — U.S. Trainees and the Ebola Epidemic. N Engl J Med. 2014 Dec 17. 
 
-----------------------------------------------------------
Sigue este Blog en Facebook y Twitter

LinkWithin

Related Posts Plugin for WordPress, Blogger...